Abivax Announces $235.8 Million IPO

New York – October 20, 2023 – Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.

Abivax offered a total of 20,325,500 ordinary shares – consisting of 18,699,460 American depositary shares and 1,626,040 ordinary shares in certain jurisdictions outside the US – priced at $11.60 per share, with a 30-day option for the underwriters to purchase up to 3,048,825 additional ordinary and/or American depositary shares. The listing is now trading on the Nasdaq Global Market under the symbol ABVX.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has over 1,300 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.